A case report of cervical cancer treated with a checkpoint inhibitor in a real-world clinical setting
https://doi.org/10.18027/2224-5057-2019-9-2-74-80
Abstract
The treatment standard for stage IVB cervical cancer is palliative drug therapy combined with cytoreductive surgery used in the presence of resectable lesions. Anticancer therapy is based on two-component regimens that include platinum agents and taxanes. The virus-associated aetiology and pathogenesis of cervical cancer is a predictor of high efficacy of immunotherapy, which made the FDA approve an anti-PD1 agent for use in the treatment of these patients in 2018. The paper presents literature data on the treatment methods for advanced cervical cancer and a case report of indolent disease that was treated with all currently available therapeutic options, including checkpoint inhibitors.
About the Authors
R. V. Orlova
Saint Petersburg State University
Russian Federation
Rashida V. Orlova - MD, PhD, DSc, Professor, Head of the Department of Oncology
Competing Interests: no conflict of interest
Russian Federation
Rashida V. Orlova - MD, PhD, DSc, Professor, Head of the Department of Oncology
Competing Interests: no conflict of interest
N. V. Tyukavina
Municipal Hospital No. 40 of Kurortnyi District
Russian Federation
Competing Interests: no conflict of interest
Russian Federation
Nina V. Tyukavina - Oncologist, Head of the Department of Oncology.
St. Petersburg
Competing Interests: no conflict of interest
M. I. Gluzman
Saint Petersburg State University; Municipal Hospital No. 40 of Kurortnyi District
Russian Federation
Mark I. Gluzman - Teaching Assistant, Chair of Faculty Surgery
Competing Interests: no conflict of interest
Russian Federation
Mark I. Gluzman - Teaching Assistant, Chair of Faculty Surgery
Competing Interests: no conflict of interest
A. E. Protasova
Saint Petersburg State University; Reproductive Medicine Clinic AVA-PETER LLC
Russian Federation
Competing Interests: no conflict of interest
Russian Federation
Anna E. Protasova - MD, PhD, DSc, Professor Department of Oncology Faculty MSPSU, Head of the Department of Oncology Clinic of Reproductive Medicine AVA-PETER LLC
Competing Interests: no conflict of interest
G. A. Raskin
Saint Petersburg State University; Russian Scientific Center of Radiology and Surgical Technologies named after Academician A.M. Granova
Russian Federation
Competing Interests: no conflict of interest
Russian Federation
Grigoriy A. Raskin - MD, PhD, DSc, Professor Department of Oncology Faculty MSPSU, Head of the Division of Pathology A.M. Granov RRCRST
Competing Interests: no conflict of interest
А. D. Khalikov
Reproductive Medicine Clinic AVA-PETER LLC
Russian Federation
Competing Interests: no conflict of interest
Russian Federation
Aziz D. Khalikov - MD, PhD, Head of the Department of MRI and CT.
St. Petersburg
Competing Interests: no conflict of interest
References
1. Bray F. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries / F. Bray, J. Ferlay, I. Soerjomataram et al. // CA: A Cancer Journal for Clincians. — 2018. — Vol. 68. — № 6. — p. 394-424
2. Parikh S. Meta-analysis of social inequality and the risk of cervical cancer/ S. Parikh, P. Brennan, P. Boffetta // Int. J. Cancer. — 2003. — Vol. 105 (5). — p. 687-691.
3. Siegel R. Cancer statistics / R. Siegel, J. Ma, Z. Zou. / CA Cancer J Clin. — 2014. — Vol. 64 (1). — p. 9-29.
4. Minion L.E. Cervical cancer — State of the science: From angiogenesis blockade to checkpoint inhibition/L.E. Minion, K.S. Tewari // Gynecol Oncol. — 2018. — Vol. 148 (3). — p. 609-621.
5. Ijaz T. Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma/T. Ijaz, P.J. Eifel, T. Burke // Gynecol Oncol. — 1998. — Vol. 70 (2). — p. 241-246.
6. Thomas G.M. Concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after radical surgery/ G.M. Thomas, A.J. Dembo, B. Black et al. // Gynecol Oncol. — 1987. — Vol. 27 (3). — p. 254-263.
7. Eskander R.N. Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer / R.N. Eskander, K.S. Tewari // Curr Opin Obstet Gynecol. — 2014. — Vol. 26 (4). — p. 314-321.
8. Monk B.J. Evidence-based therapy for recurrent cervical cancer / B.J. Monk, K.S. Tewari // J Clin Oncol. — 2014. — Vol. 32 (25). — p. 2687-2690.
9. Monk B.J. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study/B.J. Monk, M.W. Sill, D.S. McMeekin et al. // J. Clin. Oncol. — 2009. — Vol. 27 (28). — p. 4649-4655.
10. Tewari K.S. The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma/K.S. Tewari, B.J. Monk // Clin. Adv. Hematol. Oncol. — 2010. — Vol. 8 (2). — p. 108-115.
11. Tewari K.S. Improved survival with bevacizumab in advanced cervical cancer / K.S. Tewari, M.W. Sill, H.J. Long III et al. // N Engl J Med. — 2014. — Vol. 370 (8). — p. 734-743.
12. Burd E.M. Human Papillomavirus and Cervical Cancer/E.M. Burd // Clin Microbiol Rev. — 2003. — Vol. 16 (1). — p. 1-17.
13. Crosbie E.J. Human papillomavirus and cervical cancer / E.J. Crosbie, M.H. Einstein, S. Franceschi et al. // Lancet. — 2013. — Vol. 382 (9895). — p. 889-899.
14. Yang W. Increased expression of programmed death (PD) — 1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia/W. Yang, Y. Song, Y.L. Lu et al. // Immunol. — 2013. — Vol. 139 (4). — p. 513-522.
15. Howitt BE. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva / B.E. Howitt, H.H. Sun, M.G. Roemer et al. // JAMA Oncol. — 2016. — Vol. 2 (4). — p. 518-522.
16. Roszik J. Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy/J. Roszik, K.L. Ring, K.M. Wani et al. // Front Immunol. — 2018. — Vol. 9 (2102). Availeble online: doi: 10.3389/fimmu.2018.02102.
17. Hollebecque A. An Open-label, Multicohort, Phase I/II Study of Nivolumab in Patients With Virus-associated Tumors (CheckMate 358): Efficacy and Safety in Recurrent or Metastatic (R/M) Cervical, Vaginal, and Vulvar Cancers/ A. Hollebecque, T. Meyer, K.N. Moore et al. // J. Clin. Oncol. — 2017. — Vol. 35 (15 suppl) — p. 5504.
18. U.S. National Library of Medicine, https://clinicaltrials.gov/ct2/show/NCT02257528, Accessed date: 4 November 2017
19. Frenel J.S. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1positive cervical cancer: results from the phase Ib KEYNOTE-028 trial / J.S. Frenel, C. Le Tourneau, B. O»Neil et al. // J. Clin. Oncol. -2017. — Vol. 35 (36). — p. 4035-4041.
20. Chung H.C. Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study/H.C. Chung, J.H. M. Schellens, J.P. Delord et al. // Journal of Clinical Oncology. — 2018. — Vol. 36 (15_suppl). -p. 5522-5522.
21. U.S. Food and Drug Administration: FDA approves pembrolizumab for advanced cervical cancer with disease progression during or after chemotherapy. Available at www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610572.htm
Review
For citations:
Orlova R.V., Tyukavina N.V., Gluzman M.I., Protasova A.E., Raskin G.A., Khalikov А.D. A case report of cervical cancer treated with a checkpoint inhibitor in a real-world clinical setting. Malignant tumours. 2019;9(2):74-80. (In Russ.) https://doi.org/10.18027/2224-5057-2019-9-2-74-80
Views:
2275
Email this article 